VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

VAXART, INC. (VXRT) reported a Q2 2025 loss of $0.07 per share, exceeding the Zacks Consensus Estimate of a $0.09 loss, and posted revenues of $39.73 million, significantly surpassing expectations by 1,206.91% from $6.4 million a year ago. Despite this substantial revenue beat and an EPS surprise of 22.22%, VXRT shares have lost 42.6% year-to-date, considerably underperforming the S&P 500. The stock currently holds a Zacks Rank #3 (Hold), suggesting future price movement will largely depend on management's commentary during the earnings call.

Analysis

Vaxart, Inc. (VXRT) reported a mixed but noteworthy second quarter, with significant outperformance on key financial metrics contrasted by poor stock performance and uncertain forward guidance. The company posted a narrower-than-expected loss of $0.07 per share, representing a 22.22% positive earnings surprise compared to the consensus estimate of a $0.09 loss. More strikingly, quarterly revenue reached $39.73 million, a monumental 1,206.91% beat against consensus and a substantial increase from the $6.4 million reported in the prior-year period. Despite these strong results and a history of surpassing EPS estimates in three of the last four quarters, VXRT shares have plummeted 42.6% year-to-date, sharply underperforming the S&P 500. This divergence highlights significant investor skepticism, which is further underscored by the consensus estimates for the upcoming quarter projecting a steep revenue drop to just $3.29 million. The current Zacks Rank #3 (Hold) reflects this ambiguity, suggesting the market awaits further clarification, with the sustainability of any stock rebound being highly dependent on management's forthcoming commentary on the nature of the revenue beat and the company's future earnings outlook.

Key Decisions for Investors

• Investors should scrutinize the source of the exceptional Q2 revenue, as forward estimates suggest this is a non-recurring event and not indicative of a sustainable trend.
• Pay close attention to management's guidance on the upcoming earnings call, as this will be the primary catalyst determining if the recent financial beat can translate into a positive stock re-rating.
• Given the stock's severe year-to-date underperformance of 42.6% and the neutral 'Hold' rating, a cautious stance is warranted until there is clear evidence of fundamental improvement beyond a single quarter's results.